ExploreWatchlistsPricing
  1. JP-listed companies
  2. Nano Holdings, Inc.
  3. Financials
  4. Revenue growth (%)

Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Mar 31, 2025-19.9-39.60%
Mar 31, 2024-33+40.82%
Mar 31, 2023-23.4+48.98%
Mar 31, 2022-15.7-63.74%
Mar 31, 2021-43.3-482.95%
Mar 31, 202011.3-87.66%
Mar 31, 201991.7+396.59%
Mar 31, 201818.5-282.33%
Mar 31, 2017-10.1-84.17%
Mar 31, 2016-64-248.40%
Mar 31, 201543.1+63.77%
Mar 31, 201426.3+232.45%
Mar 31, 20137.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat